Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 6.47% is 74% below its 5-year average of 25.27%, near the low end of its 5-year range (3.39%–80.72%).
As of the fiscal period ended Tuesday, June 30, 2026. 6.04% above its 12-month average of 6.10%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 6.47%.
DEBT TO ASSETS RATIO
6.47%
DEBT TO ASSETS RATIO AVG TTM
6.10%
DEBT TO ASSETS RATIO AVG 3Y
4.83%
DEBT TO ASSETS RATIO AVG 5Y
25.27%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+6.04%
CURRENT VS 3Y AVG
+34.01%
CURRENT VS 5Y AVG
-74.38%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 638 covered companies
CURRENT VS SECTOR MEDIAN
+6373.65%
vs the sector median at left
CytoMed Therapeutics Limited
Market Cap
$11.24M
Debt to Assets Ratio
6.47%
TTM Avg
6.10%
3Y Avg
4.83%
5Y Avg
25.27%
Market Cap
$11.21M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$11.30M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$11.46M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$10.93M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$11.81M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CytoMed Therapeutics Limited (GDTC) | $11.24M | 6.47% | 6.10% | 4.83% | 25.27% |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $11.21M | 0.00% | N/A | N/A | N/A |
| Kiora Pharmaceuticals, Inc. (KPRX)vs › | $11.30M | 0.01% | N/A | N/A | N/A |
| BioVie Inc. (BIVI)vs › | $11.16M | 0.02% | N/A | N/A | N/A |
| Biofrontera Inc. (BFRI)vs › | $11.14M | 0.31% | N/A | N/A | N/A |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs › | $11.46M | 0.01% | N/A | N/A | N/A |
| Lisata Therapeutics, Inc. (LSTA)vs › | $10.93M | 0.00% | N/A | N/A | N/A |
| Cerenome, Inc. (CNSY)vs › | $10.81M | 0.00% | N/A | N/A | N/A |
| Lantern Pharma Inc. (LTRN)vs › | $11.81M | 0.00% | N/A | N/A | N/A |
| Lifeward Ltd. (LFWD)vs › | $10.47M | 0.32% | N/A | N/A | N/A |
Debt/Assets
6.5%
Debt/Equity
0.09
Current Ratio
2.64
Interest Coverage
-219.7x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 6.47% |
| 2025-12-31 | 6.04% |
| 2025-09-30 | 6.04% |
| 2025-06-30 | 5.86% |
| 2025-03-31 | 5.86% |
| 2024-12-31 | 4.60% |
| 2024-09-30 | 4.60% |
| 2024-06-30 | 3.93% |
| 2024-03-31 | 3.93% |
| 2023-12-31 | 3.62% |
| 2023-09-30 | 3.62% |
| 2023-06-30 | 3.39% |
| 2023-03-31 | 3.39% |
| 2022-12-31 | 80.72% |
| 2022-09-30 | 80.72% |
| 2022-06-30 | 65.22% |
| 2022-03-31 | 65.22% |
| 2021-12-31 | 53.57% |
| 2021-09-30 | 53.57% |
| 2021-06-30 | 44.93% |
| 2021-03-31 | 44.93% |
| 2020-12-31 | 78.13% |
| 2020-09-30 | 78.13% |
